RxDoctor Payments Data

Leia Ince-Mercer, MD

Internal Medicine · Hamburg, NYNPI 1962666107

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Lilly USA, LLC at 46.0% of the total. 2024 is the largest year on record at $76, 4.8 times the $16 reported in 2019. That places this record below the midpoint for internal medicine clinicians in NY, where the typical reported total is $194.

$224in general payments, 2019–2025

Across 13 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$103
  • Novo Nordisk$40
  • GSK$18
  • Pfizer$18
  • Amgen$16
  • AstraZeneca$16
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$21295%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$224 in reported general payments places this provider in the 50th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$41,459
Medicare patients
119
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$112,511
EliquisApixaban95$100,167
JardianceEmpagliflozin34$36,194
MounjaroTirzepatide33$35,559
XareltoRivaroxaban21$18,016
Repatha SureclickEvolocumab19$16,761
TrulicityDulaglutide13$15,723
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,576
Breo ElliptaFluticasone/Vilanterol19$12,103
Spiriva HandihalerTiotropium Bromide11$10,407
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$9,647
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$8,320
Levothyroxine Sodium455$7,673
SymbicortBudesonide/Formoterol Fumarate22$6,951
Rosuvastatin Calcium345$6,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$112,51196 claims
PfizerEliquis$18$100,16795 claims
Lilly USA, LLCMounjaro, Trulicity$103$51,28246 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$18$41,63473 claims
AstraZenecaSymbicort$16$6,95122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hamburg

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →